Anuh Pharma Achieves WHO Prequalification for Amodiaquine Hydrochloride to Combat Malaria
Thursday, 7 May 2026, 07:16
Anuh Pharma's WHO Prequalification Milestone
Anuh Pharma has recently secured WHO prequalification for its Amodiaquine Hydrochloride, a key anti-malarial API. This important development in malaria control strategies is set to enhance the supply chain and boost international exports of critical pharmaceutical ingredients.
Impact on Malaria Control
- The recognition by WHO emphasizes the quality and efficacy of Anuh's anti-malarial API.
- This advancement supports global health initiatives aimed at reducing malaria cases.
- Amodiaquine Hydrochloride is essential for effective treatment protocols in malaria-stricken regions.
With this approval, Anuh Pharma strengthens its position in the international market, facilitating greater access to vital anti-malarial drugs.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.